← ANALYST RATINGS · TIPRANKS
Ultragenyx Pharmaceutical (RARE): analyst forecast and price target
Analyst consensus
Moderate Buy9 Buy7 Hold0 Sell
Ratings of 16 analysts in the last 3 months · top analysts only12-month forecast
Based on 16 price targets given in the last 3 months, the average target is $29.93, the highest $68.00, the lowest $16.00. The average is +105.9% from the last price of $14.54.
Analyst ratings 21
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $16.00 | Hold | +10.0% | Initiated | 14.10.26on TipRanks 19:50 | +1.5%next day −3.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $14.00 → $15.00+7.1% | Hold | +3.2% | Reiterated | 14.10.26on TipRanks 19:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $13.50 → $14.50+7.4% | Hold | −0.3% | Upgrade | 14.10.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $14.50 → $15.00+3.4% | Hold | +3.2% | Reiterated | 14.10.26on TipRanks 19:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $14.00 → $14.50+3.6% | Hold | −0.3% | Reiterated | 14.10.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $14.50 → $15.00+3.4% | Hold | +3.2% | Reiterated | 14.10.26on TipRanks 19:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $25.00 | Buy | +71.9% | Reiterated | 14.10.26on TipRanks 11:35 | +0.9%next day +1.5% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $20.00 | Hold | +37.6% | Reiterated | 09.10.26on TipRanks 06:11 | +0.6%next day −1.1% · 5 days −4.1% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $19.00 | Hold | +30.7% | Reiterated | 08.10.26on TipRanks 21:45 | +0.6%next day −1.1% · 5 days −4.1% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.50 → $14.50+16.0% | Hold | −0.3% | Reiterated | 07.10.26on TipRanks 14:05 | — | |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $16.00 → $18.00+12.5% | Hold | +23.8% | Reiterated | 21.09.26on TipRanks 08:15 | −0.6%next day +6.6% · 5 days −0.6% | ↗ |
| Maxwell Skor★★★★★★★★★★#486 · hits 74% · avg +28.0% | Morgan Stanley | $18.00 → $20.00+11.1% | Hold | +37.6% | Assigned | 21.09.26on TipRanks Sep 18 08:25 | −0.1%next day −0.6% · 5 days −1.3% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $32.00 → $35.00+9.4% | Buy | +140.7% | Reiterated | 18.09.26on TipRanks Sep 20 21:15 | −0.1%next day −0.6% · 5 days −1.3% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $33.00 | Buy | +127.0% | Reiterated | 18.09.26on TipRanks 08:30 | −0.1%next day −0.6% · 5 days −1.3% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $23.00 | Hold | +58.2% | Reiterated | 18.09.26on TipRanks 07:50 | −0.1%next day −0.6% · 5 days −1.3% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $37.00 → $39.00+5.4% | Buy | +168.2% | Reiterated | 18.09.26on TipRanks 07:10 | −0.1%next day −0.6% · 5 days −1.3% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $18.00 | Hold | +23.8% | Assigned | 18.09.26on TipRanks 06:55 | −0.1%next day −0.6% · 5 days −1.3% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $31.00 → $32.00+3.2% | Buy | +120.1% | Reiterated | 18.09.26on TipRanks 06:45 | −0.1%next day −0.6% · 5 days −1.3% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Hold | — | Reiterated | 18.09.26on TipRanks 02:55 | −0.1%next day −0.6% · 5 days −1.3% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $33.00 → $39.00+18.2% | Buy | +168.2% | Reiterated | 17.09.26on TipRanks Sep 18 07:15 | +11.4%next day −0.1% · 5 days +1.0% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $28.00 → $19.00−32.1% | Hold | +30.7% | Reiterated | 04.09.26on TipRanks 06:55 | +3.4%next day −2.2% · 5 days −9.8% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $77.00 → $28.00−63.6% | Buy | +92.6% | Reiterated | 03.09.26on TipRanks 09:00 | −45.1%next day +3.4% · 5 days −2.6% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $80.00 → $36.00−55.0% | Hold | +147.6% | Downgrade | 03.09.26on TipRanks 05:10 | −45.1%next day +3.4% · 5 days −2.6% | ↗ |
| Jack Allen★★★★★★★★★★#12322 · hits 30% · avg −16.3% | Robert W. Baird | $40.00 → $16.00−60.0% | Hold | +10.0% | Downgrade | 03.09.26on TipRanks 05:05 | −45.1%next day +3.4% · 5 days −2.6% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $49.00 → $18.00−63.3% | Buy | +23.8% | Assigned | 03.09.26on TipRanks Sep 2 19:30 | −45.1%next day +3.4% · 5 days −2.6% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $68.00 | Buy | +367.7% | Reiterated | 17.08.26on TipRanks 07:38 | −0.9%next day −1.8% · 5 days −0.4% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $43.00 → $35.00−18.6% | Buy | +140.7% | Reiterated | 03.08.26on TipRanks Aug 4 07:51 | −1.0%next day +1.4% · 5 days +5.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Ultragenyx Pharmaceutical
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $28.47 at a price of $15.03 (+89.4%); now: $27.85 at $14.54 (+91.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 10 | 15 | 23 | 22 |
| Buy | 1 | 1 | 1 | 4 | 5 | 5 |
| Hold | 2 | 1 | 4 | 6 | 16 | 14 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.11 (from $-1.29 to $-0.66). Last quarter: $-0.90.
Sales
Next quarter’s sales estimate — $182M (from $161M to $198M). Last quarter: $214M.
Best top-analyst consensus in the sector · Healthcare
About Ultragenyx Pharmaceutical
- CEO: Emil D. Kakkis
- Employees: 1,371
- 60 Leveroni Court, Novato, CA, 94949, US
- www.ultragenyx.com
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Data from the stock’s TipRanks forecast page, read 38 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗